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1. Introduction
  Diabetes mellitus (DM) is a chronic disease that alters the 
body’s metabolism affecting virtually every system in the 
body. The statistics due to diabetes are alarming and it 
was estimated by the World Health Organization (WHO) in 
their 2008 fact sheet on diabetes that more than 180 million 
people worldwide have diabetes and the number is likely 
to more than double by 2030 (WHO, 2008). Extensive studies 
are conducted worldwide to search for treatment of diabetes. 
Due to the dismal nature of the statistics related to diabetes, 
a lot of effort is expended to control the disease through 
the use of oral medications, insulin and other lifestyle 
changes however, success has been limited. Consequently, 
the use of traditional plant extracts to treat diabetes and 
various diseases have been flourished[1]. According to the 
WHO, more than 150 plants used in the management of 
diabetes mellitus, thus study of hypoglycaemic plants is 
encouraged[2]. For example, oral administration of aqueous 
extract of Leonotis leonurus leaf has a beneficial effect 
in reducing the blood glucose levels as well as lipids[3]. 
Whereas, it was reported that the leaf and bark extracts of 
Butea monosperma produced antihyperglycemic activity 
in STZ but the results were insignificant[4]. Traditional 
plant remedies are empirically used in Asia to treat various 
diseases and ailments. Octomeles sumatrana (O. sumatrana) 
(OS), family Datiscaceae[5] is traditionally used by the 
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Kadazandusun people of Sabah, Malaysia as a tonic. The 
bark is boiled in water and taken orally to treat body ache, 
muscle sprain, bone pain and stress. Our laboratory has 
shown this plant to have potent antioxidant capacity similar 
to vitamins C and E (unpublished data). It is non-toxic as 
shown in vitro and in vivo. As a potent antioxidant capacity 
with safe extract, OS should be explored to establish new 
pharmacological possibilities for its future development and 
application. The present study was undertaken to evaluate 
the potential hypoglycemic activity of the aqueous extract of 
OS in streptozotocin (STZ)-induced diabetic rats. Effects of 
OS at different doses were compared to glibenclamide used, 
a reference hypoglycaemic drug. 
  An understanding of the many diverse signals that 
regulate glucose metabolism will aid in the development 
of pharmacological agents from OS to treat diabetes. Since 
several anti-diabetic agents, including plant derived drugs 
target the liver to decrease hepatic glucose production, 
changes in hepatic expression of the glucose metabolism 
regulating genes including  glucose transporter 2 (Slc2a2), 
phosphoenolpyruvate carboxykinase (PCK1) and glucose-
6-phosphatase (G6Pase) were determined by real time PCR 
to explore the hypoglycemic mechanism(s) of action of OS 
aqueous extract.
2. Materials and methods
2.1. Plant material
  OS barks were collected from the forest of Tambunan, 
Sabah, in the north-central region of Malaysian Borneo. 
Barks were dried, powdered and stored and protected from 
light at -20  曟 prior to further use.  
2.2. Preparation of the aqueous extract
  The extract was obtained as follows; 100 g of dried bark of 
OS was added in 1 liter of boiling water and boiled for 15 
min followed by filtration with filter paper (Milipore filter 
0.45 毺m Ref HAWP04700) and lyophilization by freeze dryer 
(Labconco, USA) into powder form. The powder was dissolved 
in water daily just before administration to experimental rats 
at the selected doses.
2.3. Animals and treatment 
  Male Sprague-Dawley rats aged 6-8 weeks (180-250 g) 
were sued in this study. They were randomly selected and 
housed under standard environmental conditions (25±1) 曟, 
12 h/12 h
light/dark cycle. Animals had free access to water and a 
standard laboratory diet (carbohydrates: 30%, proteins: 22%, 
lipids: 12%, vitamins: 3%).
2.4. Induction of experimental diabetes
  After an overnight fast, diabetes was induced by 
intraperitoenal (i.p.) injection of a freshly prepared solution of 
streptozotocin (STZ) (Sigma, St. Louis, Mo) dissolved in 0.1 M
cold sodium citrate buffer (pH 4.5) at a dose of 55 mg/kg
body weight. Animals were then allowed to drink 5% 
glucose solution overnight to overcome the drug-induced 
hyperglycaemia. Control rats were injected with citrate 
buffer alone. After 1 week, rats with fasting blood glucose 
levels of greater than 13.8 mmol/L were considered as 
diabetic and used in the present study[6].
2.5. Experimental design
  Rats were divided into six different groups; normal control 
rats were not induced with STZ and served as reference 
group. STZ diabetic control rats were given normal saline. 
Three STZ diabetic groups were treated with OS aqueous 
extract at 0.2, 0.3 and 0.5 g/kg, twice daily continuously for
21 d. The fifth group received the reference drug, 
glibenclamide (6 mg/kg) in aqueous solution orally for 21 d. 
  The doses of the extract were chosen based on dose-
response studies that were conducted earlier in our 
laboratory. Body weight, food and water consumption were 
measured weekly. Blood was collected from the eye at 
baseline and during treatment period after 1, and 2 weeks 
for glucose determination. After 21 d, blood was collected by 
cardiac puncture for ohaematology and biochemistry tests. 
At the end of this period the rats were anaesthetized with 
diethyl ether and killed by cervical dislocation. Liver was 
excised, rinsed in ice-cold saline and snapped frozen with 
liquid nitrogen within the period of 2-5 min after death, and 
stored at -80 曟 for gene expression studies. 
2.6. Parameters
  Serum glucose, alanine transaminase (ALT), aspartate 
aminotransferase (AST) urea and creatinine levels were 
measured using  reagent kits (Instrumentation Laboratory, 
USA) by ILab Chemistry Analyzer 300 PLUS (Instrumentation 
Laboratory, USA). 
2.7. Gene expression studies
2.7.1. RNA isolation
  Total RNA was isolated from fresh frozen liver tissues kept 
in liquid nitrogen, by TRI Reagent solution according to 
manufacturer’s instructions (Ambion, Austin, Texas, USA). 
The total RNA concentration was determined by measuring 
the absorbance at 260 nm. Purity of the extracted RNA was 
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determined by measuring the ratio of the optical density 
at 260 nm and 280 nm using a spectrophotometer (BioRad, 
USA) and ranged between 1.8 and 2.0. The integrity and size 
distribution of the total RNA was determined using a 1.5 
agarose gel. The 18S and 28S RNA bands were visualized 
under UV light using gel image instrumentation. 
2.7.2. Quantitative real-time PCR
  Primers specific for Slc2a2, G6Pase, PCK1 and beta-
actin genes were designed from the gene sequence of rat 
(Rattus norvegicus) adopted from the NCBI (National Center 
for Biotechnology Information) GenBank Database (www.
ncbi.nlm.nih.gov) and supplied by NextGene. GenBank 
accession number code for Slc2a2 is NM_012879.2, for 
G6pc3 is NM_176077.3, PCK1 is NM_198780.3 and for beta 
actin gene is NM_031144.2. The sequences of the primers 
and the size are shown in Table 1. Real-time PCR using 
SYBR Green chemistry was performed on a RotorGene 
6 000 cycler with a 36 well rotor (Corbett Research UK). 
The run was performed using SensiMix one-step RT-PCR 
kit with SYBR Green (Quantace, London, UK) according to 
manufacturer’s instructions. Briefly, a reaction volume of 
25 毺L contained 12.5 毺L master mix, 1 毺L of 5 毺M each 
forward and reverse primers, and 1 毺L of the template RNA 
at concentration of 100 ng. The reactions were performed 
under the following conditions: 42 曟 for 30 min (this step 
was included to synthesize cDNA), 95 曟 for 10 min, 40 
cycles at 95 曟 for 15 s, 53 曟 for 30 min and 72 曟 for 4 s. 
Data were acquired on the SYBR channel at the end of each 
extension step. Melt curves were analysed to check for the 
absence of mispriming. The possibility of a genomic DNA 
influence on the results was eliminated by use of primers. 
Each experiment was performed three times and all samples 
were run in triplicates. Expression levels for each gene 
relative to beta-actin were calculated for all samples using 
the RotorGene software (Version 1.7, Corbett Research) 
and Microsoft Excel. Analysis of gene expression data was 
carried out by ∆∆CT method of relative quantification[7]. 
2.8. Statistical analysis
  Data were expressed as mean ± SD. Statistical analysis 
was performed using analysis of variance (ANOVA) followed 
by Bonferroni post test. Differences were considered to be 
significant when P < 0.05.
3. Results
3.1. Serum glucose levels
  Serum glucose levels of the experimental period is shown 
in Figure 1. The diabetic control rats and normal control rats 
had comparable levels of blood glucose. The STZ control 
group had significantly (P<0.01) higher of serum glucose 
level compared to normal group. After three weeks of 
treatment, the diabetic rats that received OS at doses of 0.3 
and 0.5 g/kg twice a day and glibenclamide had significantly 
(P<0.05, reduced blood glucose concentrations compared 
with STZ control group. There was no significant difference 
in serum glucose levels of STZ treated rats with OS at 
different doses and STZ treated rats with glybenclamide at 
the end of the experiment period.
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Figure 1. Serum glucose levels.
Different letters within same column indicate significant difference (P 
< 0.05; n = 6).
3.2. Body weight, food and water intake
  STZ administration caused a significant decrease in the 
body weight (Figure 2). On the another hand, in STZ treated 
rats the extract at different doses produced signs of recovery 
in body weights although not to the level of normal control 
group. The body weights of the rats given glibenclamide 
were not significantly different from those diabetic control 
rats at third week of treatment. 
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Figure 2. Body weight in experimental animals (n = 6).
Different letters within same column indicate significant difference (P 
< 0.05; n = 6).
  The diabetic control rats consumed significantly more 
food (Figure 3) and water (Figure 4) compared to the normal 
group. Treatment of STZ-diabetic rats with OS (0.2-0.5 g/kg)
or glibenclamide did not appaerencally effect rats’ food or 
water intake through the three weeks of the treatment. a 
significant decreasein food and water intake were only seen 
in diabetic rats that were treated with OS at 0.5 g/kg.
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Figure 3. Food intake in experimental animals.
Different letters within same column indicate significant difference (P 
< 0.05; n = 6).
2.3. ALT and aspartate AST levels 
  The STZ control group showed significant elevations in ALT 
and AST levels compared to normal control group (Table 2). 
Administration of OS aqueous extract at different doses (0.2, 
0.3 & 0.5 g/kg) to STZ diabetic rats caused reversal of the 
elevations in ALT and AST were elicited by STZ although the 
values were not lowered to the levels shown by normal non 
diabetic control group. Creatinine levels were not affected 
by STZ or by OS or glibenclamide treatment.
  Urea levels were significantly higher in STZ diabetic 
group compared to normal control group. Neither OS nor 
glibenclamide had much effect on urea levels of diabetic 
rats.
2.4. Gene expression of glucose metabolism regulating 
enzymes Slc2a2, PCK1 and G6Pase in the liver
  Beta actin gene showed constant expression in different 
experimental groups and was therefore chosen as the 
reference gene transcript. A amplification and melting 
curves analysis were performed which resulted in single 
product specific melting temperatures as follows: beta actin 
at 84.3 曟, Slc2a2 at 82.5 曟, G6Pase at 86.6 曟 and PCK1 at 
82.3 曟 (Figure 5a, b). No primer-dimers were generated 
during the applied 40 real-time PCR amplification cycles. 
mRNA level of Slc2a2 in STZ diabetic control group were 
not significantly different from that of normal group (Figure 
6). Treatment with OS aqueous extract caused a significant 
increase in the expression of Slc2a2 mRNA level at doses of 
0.3 and 0.5 g/kg by 2 and 2.5 fold, respectively, compared to 
control diabetic rats. However no significant changes was 
observed in Slc2a2 mRNA level in treated rats with ether OS 
at 0.2 g/kg or glibenclamide (Figure 7). 
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Figure 4. Water intake in experimental animals.
Different letters within same column indicate significant difference (P 
< 0.05; n = 6).
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Figure 5. Amplification quality observed by real-time RT-PCR using 
SYBR green fluorescence history versus cycle number of target genes 
PCK1 (A), G6Pase (B) and Slc2a2 (C) and reference gene (beta actin) 
in treated and control samples. 
  As shown in Figure 8, there was a slightly reduction in the 
expression of G6Pase in normal rats when compared with 
the diabetic untreated group. mRNA levels of G6Pase was 
significantly reduced in OS treated groups at doses of 0.3 
and 0.5 g/kg by 53% and 63%, respectively, compared to 
diabetic untreated group. Whereas, no significant difference 
was observed in the mRNA levels of G6Pase genes in treated 
with 0.2 and glibenclamide (Figure 8).
A                                            B                                               C
PCK1 gene
G6Pase gene
Beta actin gene
Slc2a2 gene
Beta actin gene
Beta actin gene
Figure 6. Specific amplification of selected genes. 
A melt curve analysis of beta actin, PCK1 (A), G6Pase (B) and Slc2a2 
(C) amplification reaction demonstrating the gradual reduction in 
fluorescence as temperature increases.
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Figure 7. Effect of O. sumatrana aqueous extract at different doses on 
mRNA level of facilitated glucose transporter 2 gene (Slc2a2) in liver 
of diabetic rats. 
Different alphabets indicate significant difference (P<0.05) (n=3). 
Run was performed using real time PCR.
 
  As shown in Figure 9, there was a significant reduction 
(P<0.05) in the expression of PCK1 in the groups treated 
with OS at 0.5 g/kg when compared with the diabetic control 
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group, whereas with 0.2 and 0.3 g/kg treatment statistically 
insignificant reduction was observed when compared with 
the diabetic control group. 
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Figure 8. Effect of O. sumatrana aqueous extract at different doses on 
mRNA level of G6Pase in liver of diabetic rats. 
Different alphabets indicate significant difference (P<0.05) (n=3). 
Run was performed using real time PCR.
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Figure 9. Effect of O. sumatrana aqueous extract at different doses on 
mRNA level of Pck1 in diabetic rat’s liver. 
Different alphabets indicate significant difference (P<0.05) (n=3). 
Run was performed using real time PCR.
4. Discussion
  Diabetes mellitus (DM) is growing concern and represents 
one of the main threats to human health. Numerous 
studies have reported the potential hypoglycemic effect 
of plant aqueous extract in reducing the glucose level in 
blood in STZ induced diabetic rats[8-10]. But up to now, 
there is no a viable study about the hypoglycemic effect 
of aqueous extract from OS. Therefore, the present study 
was undertaken to investigate the hypoglycemic effect 
of aqueous extract of OS in STZ induced diabetic rats. 
Glibenclamide  was used as reference drug to compare 
the antidiabetic properties of OS. Streptozotocin has been 
widely used for inducing type I diabetes in a variety of 
animals by affecting degeneration and necrosis of pancreatic 
b-cells[11]. Further, the STZ diabetic animals may exhibit 
most of the diabetic complications, namely, myocardial 
cardiovascular, gastrointestinal, nervous, vas deferens, 
liver, kidney, and urinary bladder dysfunctions through 
oxidative stress[12]. Several workers have reported that STZ-
induced diabetes mellitus and insulin deficiency lead to 
increase blood glucose[13], by inducing necrosis of beta-
cells of the islets of langerhans, thus causing hypo-insulin 
and hyperglycemia[14]. In our study, 3 weeks treatment 
with aqueous extract of OS twice daily at different doses 
significantly reduced fasting serum glucose in STZ induced 
diabetic rat compared to STZ untreated  control  in a dose 
dependent manner (P<0.05). The result showed that the serum 
glucose levels in treated group with 0.3 g/kg and 0.5 g/kg
OS were steadily lowered during the whole experiment. 
Administration of glibenclamide to STZ induced diabetic rats 
for 21 d, resulted in significant reduction of blood glucose 
level in comparison to the STZ control group.
  The rate-limiting step in the uptake and metabolism of 
glucose by insulin target cells is glucose transport, which 
Table 1
Gene name, gene product size, and forward and reverse primer sequences that were used in real time PCR experiment.
Gene name Fragment size Forward primer Reverse primer
NM_031144.2 (Actb)a   97 ATGGTGGGTATGGGTCAG CAATGCCGTGTTCAATGG
NM_012879.2 (Slc2a2) 162 TCTGTGCTGCTTGTGGAG ACTGACGAAGAGGAAGATGG
NM_176077.3 (G6pc3) 190 ATGATGGCTGAAGACTAC ACTTGAAGACGAGGTTGAG
NM_198780.3 (Pck1) 171 AACGTTGGCTGGCTCTC GAACCTGGCGTTGAATGC
aGene used for normalization.
Table 2
AST, ALT, creatinine and urea levels (n = 6).
Groups AST ALT Creatine (mg/dL) Urea (mg/dL)
xControl   90.0依24.4a   54.00依20.10a 0.42依0.04a 26.00依7.60a
stzControl 313.3依86.2b 230.20依63.60b 0.30依0.08a 70.80依13.50b
stz0.2 g/kg OS 201.5依68.8c 199.00依98.00a 0.31依0.10a 67.30依14.10a
stz0.3 g/kg OS 184.8依41.7c   64.80依27.00a 0.31依0.10a 72.30依36.70a
stz0.5 g/kg OS 154.8依63.0c   46.50依14.20a 0.55依0.09a 42.30依27.40a
stzGlibenclamide 160.7依53.5c 103.20依42.70a 0.29依0.10a 54.30依26.60a
Different letters within same column indicate significant difference (P< 0.05).
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is mediated by specific glucose transporters of the plasma 
membrane. Among various glucose transport systems, 
the liver plays a dual role, as glucose uptake occurs from 
circulation when gluconeogenesis and glycogenolysis are 
low; however, glucose is released when gluconeogenesis and 
glycogenolysis are activated[15]. In the present study, hepatic 
Slc2a2 expression was higher in diabetic STZ animals 
compared to normal rats. Friedman et al[16], have shown that 
the expression of hepatic Glut2 was increased in diabetic 
animals compared to normal rats. In contrast to the hepatic 
Glut2, the liver Slc2a2 expression was significantly higher in 
the treated groups with SO at 3 and 0.5 g/kg when compared 
with the control group. 
  The treatment significantly reduced the expression of the 
gene encoding the regulatory enzyme of gluconeogenesis and 
glycogenolysis (G6Pase and PCK1) in the liver of STZ rats. 
These results indicate that OS extract affect the last step in 
gluconeogenesis and glycogenolysis. Glucose is formed from 
gluconeogenic precursors in liver, and also from glycogen in 
liver. Both gluconeogenesis and glycogenolysis result in the 
formation of glucose 6-phosphate (Glc-6-P), which has to be 
hydrolysed by G6Pase before being released as glucose into 
the circulation. G6Pase thus plays a critical role in blood 
glucose homoeostasis.
  The present study reveals that aqueous extract of OS, 
represses hepatic PCK1 and G6Pase gene expression. 
Because of insulin level was not measured in the present 
study, so we were not able to address weather if any 
stimulation of insulin secretion is likely to have taken place 
after administration of the extract. Subsequently, some 
hypothetical suggestions can be made, that the plasma 
glucose lowering effect in the absence of plasma insulin 
concentration suggests that OS treatment may involve in 
an insulin independent mechanism. It can be postulated 
to involve an antioxidant mechanism as study from our 
laboratory has shown that OS aqueous extract was shown to 
be a potent antioxidant (not published data).
  Glucose transporter 2 (Slc2a2), is present in the liver under 
both gluconeogenic and glycolytic conditions. Under the 
former condition, Slc2a2 activity would be essential for 
both glucose secretion and keeping the intracellular Glu-
6-P concentration low and thus avoid permanent activation 
of glycolytic and lipogenic genes[17]. In the present study, 
thus, increase the expression of hepatic GLUT2 might add 
another efficient mechanism through response to insulin 
action. Two groups[18], reported in murine hepatocytes that 
GLUT2 and the insulin receptor (IR) seemed to colocalize 
and cointernalize in the endosomal fraction in response to 
insulin action. Such IR-GLUT2 complexes were increased in 
a mouse model of improved hepatic insulin sensitivity[19].
  STZ inductions caused a significant reduction in the 
body weight gain of the rats (diabetic control group) and 
were significantly lower than non-diabetic control rats. 
Polyuria, characteristic symptom of diabetes that could 
be a factor for the lowered body weights of STZ-diabetic 
rats compared to control rats[20]. Other studies showed that 
plant extracts may by themselves contribute to body weight 
loss in animals[21]. However, oral administration of OS 
aqueous extract to STZ-diabetic rats did not much change 
the body weights of the STZ-diabetic rats. Diabetic rats 
treated with Syzygium cordatum leaf extract did not cause 
any significant differences in body weight compared to the 
untreated rats[22]. In our study, STZ induced  diabetic rats 
were shown a significant higher level of the average food 
and water consumption than the normal rats and than that in 
the STZ treated rats groups, which seems to be due to STZ. 
Our findings are in agreement with the previous findings 
reported[23]. Serum ALT and AST levels were determined 
to evaluate the hepatic functions in hyperglycemia rats. 
Measurement of enzymatic activities of aminotransferase 
(AST and ALT) is of clinical and toxicological importance, as 
changes in their activities are indicative of tissue damage 
by toxicants or in disease conditions[24]. In normal rats, the 
normal level of serum AST, ALT in treated and untreated rats 
suggests that the extract may not be toxic at least to the liver 
at the concentration employed. However, the results of our 
study showed that STZ diabetes in rats caused significant 
increases in the levels of AST and ALT in diabetic rats, 
these findings were also reported by many other workers[25]. 
Voss et al[26], proposed that STZ in hyperglycemic animals 
caused a time dependent rise in AST and ALT levels. 
Elevated levels of these transaminases could be responsible 
for the increased gluconeogenesis and ketogenesis that 
are observed in diabetes[27,28]. Therefore, treatment with 
OS at different doses caused significant reduction of AST 
and ALT compared to untreated STZ diabetes  rats in a 
dose dependent manner, that`s suggested that the OS 
prevented liver damage further studies should carried out 
to investagate this activity and the mechanism of action. 
The diabetic hyperglycemia induces elevation of the serum 
levels of urea which were considered as significant markers 
of renal dysfunction[29]. The result show there was significant 
increase in the level of serum urea in the diabetic control 
groups compare with the non diabetic control groups.
  In conclusion, the aqueous extract of OS was found to be 
effective for improving the hyperglycemia in STZ induced 
diabetic rats by reducing the expression of G6Pase and PCK1 
genes while increasing the expression of Slc2a2 gene in the 
liver tissue.
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